EC
Innosuisse and Health~Holland (EUREKA CH-NL bilateral call)

EUREKA CH-NL Call: Cell and Gene Therapy Towards Clinical Practice

Funds joint Swiss-Dutch R&D projects moving cell and gene therapies toward clinical use.

ClosedInnosuisse and Health~Holland (EUREKA CH-NL bilateral call)SwitzerlandNetherlands

Switzerland and the Netherlands jointly run this bilateral call, managed nationally by Innosuisse and the Netherlands Enterprise Agency alongside Health~Holland and the Swiss Federal Office of Public Health. Applicants first submit a Project Outline, get recommendations, then submit a Full Project Proposal; each country funds its own partners in the approved project under its own national rules, a

The call wants translational research and clinical development projects in cell and gene therapy that bring together manufacturers, academia, payers, providers and patient advocacy groups. It is aimed at making these therapies effective, sustainable and affordable, and at cutting the regulatory friction that slows their path to market.

CycleiHow often this grant runs - e.g. annually, on a rolling basis, or a one-off call.No fixed schedule
Next deadlineiThe next date applications are due. Rolling means you can apply any time.-
Decision timeiTypical time from the deadline to the funder's decision.-
Project durationiHow long the funded work is expected to run.-
Award typeiThe form of funding - grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.-
Funding pooliThe total budget available across all awards in this round.€4M

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see the timeline

Sign up free to see where teams trip up

Guides for this application

All guides →